Home Featured Page 243

Featured

Latest

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona

Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine

Usona Files Psilocybin for Depression NDA as Race With Compass Tightens

Jackie Tileston: Nondual Mysticism, 5-MeO-DMT, and the Trouble with Psychedelic Art

Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded...

MindMed Announces Strategic Research Collaboration with Sphere Health

PT265 – Jessica Cadoch, MA – Cooperation, Drug Exceptionalism, and 12-step...

Lobe Sciences and the World Boxing Association Announce Initiative Targeting mTBI...

Psychedelic Bulletin: Delix Raises $70m Series A; Toronto Gets Psychedelics Research...

PTSF79 – Psychedelic Facilitator Abuse and Space Holding Ethics with Dr....

MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors...

MINDCURE Announces Commencement of Trading on the OTCQX Best Market

Psyence Group and Pure Extracts Finalize “Pure Psyence,” A Joint Venture...

PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors

EDITOR PICKS

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic...

Compass Says NDA Will Be Filed Within Two Weeks, Declines to...

Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.